Direct-acting antiviral (DAA) actions in treatment-naïve patients - 14/01/12
Correspondence.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 7 |
| Iconografia | 8 |
| Video | 0 |
| Altro | 0 |
Summary |
The introduction of telaprevir (TVR) and boceprevir (BOC), the first approved protease inhibitors against hepatitis C virus (HCV), into clinical practice represented the start of an exciting new era of HCV treatment. In addition to improving sustained virological response (SVR) rates in HCV genotype-1 treatment-naïve patients, these drugs administered as a triple combination with pegylated interferon (pegIFN) and ribavirin (RBV) provide opportunities for more patients to receive shorter durations of treatment (24–28 weeks) than with pegIFN/RBV alone (48 weeks). Also, the use of TVR and BOC is being enhanced by the acquisition of further data on predictors of SVR, thereby increasing patients’chances of being cured of their HCV infection.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : DAAs, pegIFN, RBV, SVR
Mappa
Vol 35 - N° S2
P. S52-S58 - Dicembre 2011 Ritorno al numero
Articolo precedente
- Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance
- Stéphane Chevaliez
- Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients
- Hélène Fontaine, Stanislas Pol
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?